At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 56 enrolled

Drug / intervention

Vorinostatdrug

Likely dose

Vorinostat 100 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00875056

NCT00875056Phase 2Completed

Compare CT.gov

A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)

Merck Sharp & Dohme LLC·interventional·Posted Apr 3, 2009·Updated Jan 30, 2026

In Brief

A Phase 2 clinical trial evaluating Vorinostat for Lymphoma. Completed, enrolled 56 participants.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma. The exploratory purpose of this study is to evaluate efficacy of MK-0683 in participants with relapsed/refractory non-FL indolent B-NHL or relapsed/refractory MCL. The primary hypothesis is that MK-0683 will show efficacy in relapsed/refractory FL patients as measured by the Overall Response Rate.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLymphoma

Countries--

Collaborators--

Timeline

Phase 2CompletedFinished

200920102011201220132014201520162017201820192020202120222023202420252026

First PostedApr 2009

Enrollment StartApr 2009

Primary CompletionSep 2011

Study CompletionFeb 2019

TodayJul 2026

First PostedApr 3, 2009

Enrollment StartApr 15, 2009

Primary CompletionSep 6, 2011

Study CompletionFeb 8, 2019

TodayJul 2, 2026

Enrollment to primary: 2.4 yearsPosted 17.2 years ago

Interventions

Vorinostatdrug

Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle